bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of “Hold” from Brokerages

bluebird bio, Inc. (NASDAQ:BLUE) has earned a consensus rating of “Hold” from the eight analysts that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $44.60.

BLUE has been the topic of several research reports. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. StockNews.com started coverage on bluebird bio in a research report on Friday, March 28th. They issued a “sell” rating for the company. Barclays cut their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday. Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lowered their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BLUE. Regeneron Pharmaceuticals Inc. bought a new stake in bluebird bio during the fourth quarter worth $175,000. Barclays PLC boosted its holdings in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 184,605 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after acquiring an additional 166,771 shares in the last quarter. State Street Corp raised its holdings in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Trading Up 7.6 %

NASDAQ BLUE opened at $5.25 on Friday. The stock has a market capitalization of $51.04 million, a P/E ratio of -0.14 and a beta of 0.76. The business has a 50 day simple moving average of $5.40 and a 200 day simple moving average of $7.63. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a one year low of $3.56 and a one year high of $28.60.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.